May 7 - 9
Bruges, BE
Visit our booth #S4
Meet the Lunaphore Team
Mark your calendars for the Immune Niches in Cancer and Inflammation Conference in Bruges!
Join us and engage directly with our specialists to discover spatial multiomics on COMET™. Experience firsthand how you can simultaneously detect RNA and proteins within the same section, all at a subcellular level of detail.
Our protease-free, fully automated workflow enables multiomics scalability for all stages of research. Are you interested in elevating your spatial biology projects with our multiomics solutions? Come along to booth S4 to find out more.
See below for Lunaphore’s schedule. More information can be found on the official website.
Schedule
May 7 - 9
Poster Presentation
During poster sessions
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success. We have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™) (Rivest et al, 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and using standard, non-conjugated primary antibodies for protein detection. Lunaphore’s HORIZON™ software was used to analyze the multiomics dataset.
We have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using RNA probes targeting IFNG, TNFA, TGFB1, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68. We were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12 and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
Our study showcased same-section RNA-protein detection to profile the TME, revealing distinct tumor phenotypes potentially linked to immunosuppressive or immunostimulatory environments. Mapping TME components could better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Cansaran Saygili Demir, Ph.D.
Application Development Scientist
Lunaphore Technologies
May 7 - 9
Poster Presentation
During poster sessions
Checkpoint and engineered immune cell therapies are crucial in cancer treatment. Understanding checkpoint markers, immune cell biology, and cell interactions in the tumor environment (TME) through spatial visualization can optimize treatment success. We have developed a fully automated spatial multiomics protocol on the COMET™ platform that enables RNA detection using the RNAscope™ HiPlex Pro assay combined with protein detection using sequential immunofluorescence (seqIF™) (Rivest et al, 2023) to integrate same-section sequential detection of up to 12 RNAs followed by up to 24 proteins. This workflow allows the detection of any RNA and protein target of interest by utilizing existing RNAscope probes or generating a custom design for any RNA target and using standard, non-conjugated primary antibodies for protein detection. Lunaphore’s HORIZON™ software was used to analyze the multiomics dataset.
We have demonstrated the precise spatial profiling of FFPE solid tumors through the detection of key cytokines indicative of activated T cells and macrophages by using RNA probes targeting IFNG, TNFA, TGFB1, IL-6, IL-8, IL-10 among others in combination with cell marker antibodies detecting CD3, CD8, CD4, FOXP3 and CD68. We were also able to visualize T cell recruiting chemokines and receptors such as CXCL10, CXCL9, CXCL13, CXCL12 and CXCR3, and spatially map tumor-infiltrating T cells within tissue context and with subcellular resolution.
Our study showcased same-section RNA-protein detection to profile the TME, revealing distinct tumor phenotypes potentially linked to immunosuppressive or immunostimulatory environments. Mapping TME components could better predict therapeutic response for checkpoint and immune-based therapies.
Speaker
Cansaran Saygili Demir, Ph.D.
Application Development Scientist
Lunaphore Technologies